Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03200587 · ClinicalTrials.gov registry record · Phase 1
Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)
A Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03200587 is a Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 12 participants.
The verdict
NCT03200587, a Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open-label, non-controlled, non-randomized, phase I dose-finding, of Cabometyx + Avelumab, to establish safety, feasibility, and the maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D) of Cabometyx in combination with Avelumab, and to investigate preliminary efficacy. The MTD or RP2D determined in this study will be used for a future study to formally test efficacy. The MTD determined by dose escalation will be the recommended Phase 2 dose.
Interventions
- DRUG Cabozantinib
- DRUG Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2021-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03200587
The ClinicalTrials.gov registry entry for NCT03200587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cabozantinib is the first listed.
NCT03200587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03200587 about?
NCT03200587 is a clinical study titled "Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)". This is an open-label, non-controlled, non-randomized, phase I dose-finding, of Cabometyx + Avelumab, to establish safety, feasibility, and the maximum tolerated dose (MTD) or Recommended Phase 2 Dose (RP2D) of Cabometyx in combination with Avelumab, and to investigate preliminary efficacy. The MTD ...
What is the current status of trial NCT03200587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2018-06-21. Estimated completion is 2021-11-25.
What interventions are being tested in trial NCT03200587?
The interventions under investigation include: Cabozantinib (DRUG), Avelumab (DRUG).
Who is sponsoring clinical trial NCT03200587?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.